title: Rewards in practice from chrono-meta-analyses 'recycling' heart rate, ectopy, ischemia and blood pressure information.
abstract: Previously published average curves of heart rate and duration of ischemia in patients with coronary artery disease, studied while on placebo or on treatment with either atenolol or diltiazem, are re-analysed for the assessment of about-daily (circadian) and about-weekly (circaseptan) changes in these variables and of any treatment effect on rhythm characteristics. In addition to circadians, a circaseptan pattern characterizes the duration of ischemia in all three aforementioned study stages. Both drugs decrease the duration of ischemia, atenolol, but not diltiazem, also affects the circadian amplitude and acrophase of this variable. A circaseptan pattern is also found for heart rate on placebo and on treatment with atenolol, but not with diltiazem. Both drugs lower heart rate and the circadian amplitude and 24-h standard deviation of heart rate, atenolol much more markedly than diltiazem. Circadian and circaseptan rhythm characteristics and their alterations with treatment serve to optimize treatment by timing its administration. Chronobiologic surveillance of variables that are being readily monitored as-one-goes by modern implantable devices can also serve for the validation of the effectiveness of drug and electrical therapy. Rhythm alterations, in turn, can provide the earliest warnings of an elevated disease risk and lead to an improved diagnosis.
authors.affiliation: Chronobiology Laboratories, University of Minnesota, Minneapolis, USA.
authors.forename: F
authors.initials: F
authors.lastname: Halberg
authors.forename: G
authors.initials: G
authors.lastname: Cornélissen
authors.forename: K
authors.initials: K
authors.lastname: Otsuka
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
authors.forename: M A
authors.initials: MA
authors.lastname: Wood
authors.forename: C R
authors.initials: CR
authors.lastname: Lambert
authors.forename: R
authors.initials: R
authors.lastname: Zaslavskaya
authors.forename: D
authors.initials: D
authors.lastname: Gubin
authors.forename: E
authors.initials: E
authors.lastname: Yuryevna Petukhova
authors.forename: P
authors.initials: P
authors.lastname: Delmore
authors.forename: E
authors.initials: E
authors.lastname: Bakken
mesh_terms: D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy*; D002940:Circadian Rhythm / Q000187:drug effects; D003327:Coronary Disease / Q000175:diagnosis / Q000188:drug therapy*; D004110:Diltiazem / Q000627:therapeutic use*; D015716:Electrocardiography, Ambulatory / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D001262:Atenolol; D004110:Diltiazem